Abstract
The development of targeted therapies (Braf/MEK inhibitors) and immunotherapy have had a major impact on the treatment of melanoma. However, the majority of patients with advanced melanoma succumb to their disease. The mechanisms of resistance to both targeted therapies and immunotherapies are numerous and have been well described. These include alternative activation of Braf/MEK signaling, novel compensating mutations in additional oncogenes, and loss of neoantigens. Thus, there is an urgent need for novel therapies for advanced melanomas utilizing additional mechanisms of action.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
